M ounjaro is the brand name for tirzepatide, a prescription medication developed by Eli Lilly that is primarily used to treat type 2 diabetes in adults. It is a once-weekly inject ...

New research compared the effect of semaglutide vs. tirzepatide on weight loss over a 72 week period. Here's what the study ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

Adults receiving tirzepatide lost more weight and had a greater decline in waist circumference than those receiving semaglutide. The proportion of adults experiencing adverse events was similar in ...

MÁLAGA, Spain — In the first head-to-head trial of its kind, tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity; Eli Lilly) produced significantly greater weight loss ...

A major 72-week trial shows tirzepatide leads to double-digit weight loss and greater waist reduction than semaglutide, reshaping obesity treatment strategies and offering new hope for patients ...

The SURMOUNT-5 trial, published over the weekend in the New England Journal of Medicine and presented at the European Congress on Obesity, showed that treatment with tirzepatide (Zepbound; Eli Lilly) ...

Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 ...